TURKU, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, will report ...

Tuomas Toropainen (b. 1980) has been appointed as CFO of Siili Group and a member of the management team. He will assume his duties as CFO on 1 September 2025 and will report to CEO Tomi Pienimäki.

Tokmanni Group Corporation has appointed a third-party broker as the lead manager for the buyback program. The broker will make trading decisions independently, without influence from Tokmanni Group ...

During the subscription window of Canatu Plc’s (the “ Company ”) option rights 2024-I between 8 April 2025 and 30 June 2025, a total of 8,400 new series A shares in the Company have been subscribed ...

The arbitral tribunal appointed by the Redemption Board of the Finland Chamber of Commerce in connection with the redemption proceedings concerning the minority shares in Heeros Plc (“Heeros”) has ...

Viking Line Abp HALF YEAR FINANCIAL REPORT August 15, 2025 9.00 AM A challenging half-year with improved results in the second quarter. SECOND QUARTER OF 2025 (compared to the sec ...

Half Year financial report. Gofore Plc Half-year Report 14 August 2025 at 8.45 a.m. EET . Gofore Plc’s Half-year Report January-June 2025: ...

- The Tulikivi Group’s net sales were EUR 8.5 million (Q2/2024: EUR 9.3 million) in the second quarter and EUR 14.6 million (H1/2024: EUR 17.8 million) in the review period. - The Tulikivi Group’s ...

Aspo has today signed an agreement to divest its Leipurin business to Lantmännen at an enterprise value of EUR 63 million. The estimated cash consideration payable at closing is approximately EUR 60 ...

This company announcement is a summary of Bioretec Ltd's half-year report for January-June 2025. The complete half-year report with tables is attached to this release as a pdf file and available at ...

Eezy Plc's Half-Year Report 1–6/2025: Chain-wide revenue in line with market development, profit improvement program prog ...

Administer seeks to continue growth investments as well as organic and inorganic growth in 2025. Administer estimates that its net sales will be EUR 72–78 million and its EBITDA margin will be 7–10% ...